Results 21 to 30 of about 437,752 (336)
Proteolysis-Driven Oncogenesis [PDF]
Cell Cycle, 2007 An elevated expression of matrix metalloproteinases (MMPs) has been correlated with the growth and metastasis of preexisting tumors. The latest data, however, suggest that MMPs, by promoting genomic instability, are directly involved in the early stages of cell transformation from normalcy to malignancy and in incipient cancer.
Vladislav S, Golubkov, Alex Y, Strongin
openaire +2 more sources
Journal of Biological Chemistry, 1977 A rapid and convenient method for peptide mapping of proteins has been developed. The technique, which is especially suitable for analysis of proteins that have been isolated from gels containg sodium dodecyl sulfate, involves partial enzymatic ...
D. Cleveland +3 more
semanticscholar +1 more source
PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics
Oncogene, 2020 Using PROteolysis TArgeting Chimeras (PROTACs) to degrade proteins that are important for tumorigenesis has emerged as a potential therapeutic strategy for cancer. PROTACs are heterobifunctional molecules consisting of one ligand for binding to a protein
Sajid Khan +7 more
semanticscholar +1 more source
Trends in Genetics, 1999 Our present understanding of intracellular protein degradation developed from an attempt to understand the metabolic stability of proteins in cells. With the unravelling of its complex biochemical machinery has come a realization that protein degradation plays an important role in the most crucial events in the cell cycle, in signal transduction and in
M, Staszczak, E, Zdunek
openaire +4 more sources
Nanomechanical in situ monitoring of proteolysis of peptide by Cathepsin B. [PDF]
PLoS ONE, 2009 Characterization and control of proteolysis of peptides by specific cellular protease is a priori requisite for effective drug discovery. Here, we report the nanomechanical, in situ monitoring of proteolysis of peptide chain attributed to protease ...
Taeyun Kwon +9 more
doaj +1 more source
Proteolysis‐targeting chimeras in drug development: A safety perspective
British Journal of Pharmacology, 2020 Proteolysis‐targeting chimeras are a new drug modality that exploits the endogenous ubiquitin proteasome system to degrade a protein of interest for therapeutic benefit.
K. Moreau +8 more
semanticscholar +1 more source
The regions of the sequence most exposed to the solvent within the amyloidogenic state of a protein initiate the aggregation process. [PDF]
, 2004 Formation of misfolded aggregates is an essential part of what proteins can do. The process of protein aggregation is central to many human diseases and any aggregating event needs to be prevented within a cell and in protein design.
AMORESANO, ANGELA +6 more
core +1 more source
Epigenetics & Chromatin, 2023 Background Proteolysis of the histone H3 N-terminal tail (H3NT) is an evolutionarily conserved epigenomic feature of nearly all eukaryotes, generating a cleaved H3 product that is retained in ~ 5–10% of the genome.
Benjamin H. Weekley, Judd C. Rice
doaj +1 more source
PROteolysis TArgeting Chimeras (PROTACs) - Past, present and future.
Drug Discovery Today : Technologies, 2019 The majority of currently used therapeutics are small molecule-based and utilize occupancy-driven pharmacology as the mode of action (MOA), in which the protein function is modulated via temporary inhibition. New modalities that operate using alternative
M. Pettersson, C. Crews
semanticscholar +1 more source
Harnessing the Power of Proteolysis for Targeted Protein Inactivation.
Molecules and Cells, 2020 Two decades into the twenty-first century, a confluence of breakthrough technologies wielded at the molecular level is presenting biologists with unique opportunities to unravel the complexities of the cellular world.
R. Verma, D. Mohl, R. Deshaies
semanticscholar +1 more source